Patents by Inventor Shari L. Caplan

Shari L. Caplan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dual function fibroblast growth factor 21 proteins
    Patent number: 9458214
    Abstract: The present invention relates to dual function fusions proteins comprising fibroblast growth factor 21 (FGF21) and Exenatide, Exendin-4, or GLP-1. Also disclosed are methods for treating FGF21-associated disorders, GLP-1-associated disorders, and Exendin-4-associated disorders, including metabolic conditions.
    Type: Grant
    Filed: September 25, 2012
    Date of Patent: October 4, 2016
    Assignee: NOVARTIS AG
    Inventors: Brian R. Boettcher, Shari L. Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon, Susan E. Cellitti, Bernhard Hubert Geierstranger, Andreas Loew
  • METHODS OF TREATING FGF21-ASSOCIATED DISORDERS
    Publication number: 20160051628
    Abstract: The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
    Type: Application
    Filed: April 2, 2015
    Publication date: February 25, 2016
    Applicants: IRM LLC, NOVARTIS AG
    Inventors: Brian R. BOETTCHER, Andreas LOEW, Shari L. CAPLAN, Douglas S. DANIELS, Bernhard H. GEIERSTANGER, Norio HAMAMATSU, Stuart LICHT, Stephen Craig WELDON
  • Methods of treating metabolic disorders with an FGF21 variant
    Patent number: 9266935
    Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: February 23, 2016
    Assignee: Novartis AG
    Inventors: Brian R. Boettcher, Shari L. Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
  • FUSION PROTEINS FOR TREATING METABOLIC DISORDERS
    Publication number: 20150166622
    Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
    Type: Application
    Filed: February 24, 2015
    Publication date: June 18, 2015
    Inventors: Brian R. Boettcher, Shari L. Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
  • Fibroblast growth factor 21 mutations
    Patent number: 9023791
    Abstract: The present invention provides novel polypeptide and protein variants of fibroblast growth factor 21 (FGF21) and pharmaceutical compositions comprising FGF21 polypeptide and protein variants.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: May 5, 2015
    Assignees: Novartis AG, IRM LLC
    Inventors: Brian R. Boettcher, Shari L. Caplan, Douglas S. Daniels, Bernhard H. Geierstanger, Norio Hamamatsu, Stuart Licht, Andreas Loew, Stephen Craig Weldon
  • Fibroblast growth factor-21-Fc fusion proteins
    Patent number: 9006400
    Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
    Type: Grant
    Filed: September 25, 2012
    Date of Patent: April 14, 2015
    Assignee: Novartis AG
    Inventors: Brian R. Boettcher, Shari L. Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
  • FUSION PROTEINS FOR TREATING METABOLIC DISORDERS
    Publication number: 20130079500
    Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
    Type: Application
    Filed: September 25, 2012
    Publication date: March 28, 2013
    Inventors: Brian R. Boettcher, Shari L. Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
  • METHODS OF TREATING FGF21-ASSOCIATED DISORDERS
    Publication number: 20120129766
    Abstract: The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
    Type: Application
    Filed: November 15, 2011
    Publication date: May 24, 2012
    Applicants: IRM LLC, NOVARTIS AG
    Inventors: Brian R. BOETTCHER, Shari L. CAPLAN, Douglas S. DANIELS, Bernhard H. GEIERSTANGER, Norio HAMAMATSU, Stuart LICHT, Andreas LOEW, Stephen Craig WELDON
  • Methods and compositions for treatment of diabetes and related conditions via gene therapy
    Patent number: 6608038
    Abstract: Disclosed are methods and compositions for treatment of diabetes, obesity and diabetic-related conditions. The methods include gene therapy based administration of a therapeutically effective amount of vectors encoding the following: glucokinase regulatory protein alone or co-administered with glucokinase or with metabolism modifying proteins; glucokinase co-administered with metabolism modifying proteins; or glucokinase regulatory protein co-administered with glucokinase in combination with metabolism modifying proteins, to a diabetic patient. Wherein the metabolism modifying proteins include UCP2, UCP3, PPAR&agr;, OB-Rb, GLP-1 and GLP-1 analogs (administered via vector or directly as a peptide). Preferred examples of GLP-1 analogs include GLP-1-Gly8, Extendin-4 and the “Black Widow” chimeric GLP-1 analog. Additionally, PPAR&agr; ligands and DPP-IV inhibitors may be co-administered with the above.
    Type: Grant
    Filed: March 14, 2001
    Date of Patent: August 19, 2003
    Assignee: Novartis AG
    Inventors: Shari L. Caplan, Brian R. Boettcher, Eric D. Slosberg, Sheila Connelly, Michael Kaleko, Urvi J. Desai
  • Methods and compositions for treatment of diabetes and related conditions via gene therapy
    Publication number: 20020065239
    Abstract: Disclosed are methods and compositions for treatment of diabetes, obesity and diabetic-related conditions. The methods include gene therapy based administration of a therapeutically effective amount of vectors encoding the following: glucokinase regulatory protein alone or co-administered with glucokinase or with metabolism modifying proteins; glucokinase co-administered with metabolism modifying proteins; or glucokinase regulatory protein co-administered with glucokinase in combination with metabolism modifying proteins, to a diabetic patient. Wherein the metabolism modifying proteins include UCP2, UCP3, PPAR&agr;, OB-Rb, GLP-1 and GLP-1 analogs (administered via vector or directly as a peptide). Preferred examples of GLP-1 analogs include GLP-1-Gly8, Extendin-4 and the “Black Widow” chimeric GLP-1 analog. Additionally, PPAR&agr; ligands and DPP-IV inhibitors may be co-administered with the above.
    Type: Application
    Filed: March 14, 2001
    Publication date: May 30, 2002
    Inventors: Shari L. Caplan, Brian R. Boettcher, Eric D. Slosberg, Sheila Connelly, Michael Kaleko, Urvi J. Desai